Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

NCT07529782 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma and Other Plasma Cell Neoplasms

Interventions

DRUG: HDP-101

Sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Collaborators

[object Object]